trastuzumab,tucatinib
seagen
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
few abstracts from day1 tucatinib and trastuzumab in her2 biliary tract cancer: 46.7% orr, 1 cr mdor: 6 months pfs and os: 5.5 and 15.5 months, respectively. #asco2023 
Assistant Professor, GI Onc @OSUCCC_James @EinsteinMed Alum| @ClevelandClinic Alum| Interested in Drug Development|Precision Oncology|Cancer Disparities